Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild type primary glioblastoma
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild type primary glioblastoma
- 20/03/2023
- 113 samples
- DAC: EGAC00001003085
- Technology: Illumina HiSeq 2500
Samsung Medical Center (SMC) - Institute for Refractory Cancer (IRCR) Data Access Policy
SMC-IRCR data access policy generally respects the guidelines of NIH genomic data sharing policy (http://gds.nih.gov/PDF/NIH_GDS_Policy.pdf), but can be overridden by consensual decision of DAC in exceptional cases.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001006989 | Other |
